top of page
Profile
Join date: Mar 23, 2023
Posts (34)
Mar 11, 2025 ∙ 4 min
Laxxon's Oral GLP-1 Agonist Treatment, LXM.2, Granted Funding by ESF Plus and the Free State of Thuringia
Laxxon has received a grant by Freistaat Thüringen and the ESF Plus (European Social Fund) for the further development of LXM.2.
35
0
Jan 15, 2025 ∙ 3 min
Laxxon Medical Announces Positive Pilot PK Study Results (in Pigs) for Groundbreaking Oral GLP-1 Dosage Form
[New York, New York] – Laxxon Medical, a leading pharmaceutical technology company pioneering a new generation of advanced oral drug...
216
0
Jan 7, 2025 ∙ 1 min
Laxxon Medical to Participate in 27th Annual Needham Growth Conference
NEW YORK, NY / ACCESSWIRE / January 7, 2024 / Laxxon Medical, a leading pharma-technology company pioneering a new generation of...
28
0
Laxxon Medical
Writer
More actions
bottom of page